Trials / Completed
CompletedNCT02273895
The Use of EEG in Alzheimer's Disease, With and Without Scopolamine - A Pilot Study
Development of a Diagnostic Tool for Alzheimer's Disease
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Mentis Cura · Industry
- Sex
- All
- Age
- 60 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to compare the electroencephalography (EEG) responses of three distinct groups of individuals to scopolamine: 1) a group of Alzheimer Dementia (AD) patients, 2) a group of individuals suffering from Mild Cognitive Impairment (MCI) and 3) a group of controls. The main purpose of this comparison is to discover ways to use these responses to distinguish between the group of AD patients and controls in order to develop a diagnostic tool for AD. The purpose of including the MCI group is to investigate whether this diagnostic tool can predict which member of the MCI group will develop AD later in life.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Scopolamine | 0.3 mg/mL, intravenously, once |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2004-10-01
- Completion
- 2010-01-01
- First posted
- 2014-10-24
- Last updated
- 2014-10-24
Source: ClinicalTrials.gov record NCT02273895. Inclusion in this directory is not an endorsement.